Cardiovascular somatic symptom disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:37:33 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cardiovascular somatic symptom disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Cardiodoron Dilution for Patients with Functional Cardiovascular Disorders https://clinicaltrials.eu/trial/study-on-the-effects-of-cardiodoron-dilution-for-patients-with-functional-cardiovascular-disorders/ Wed, 29 Apr 2026 15:01:38 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-cardiodoron-dilution-for-patients-with-functional-cardiovascular-disorders/ This clinical trial is focused on studying the effects of a treatment called Cardiodoron® in patients with functional cardiovascular disorders. These disorders affect the heart and blood vessels, causing symptoms like irregular heartbeats or chest discomfort, but without any structural heart disease. The treatment being tested is an oral solution made from natural ingredients, including Onopordum acanthium and Primula veris, combined with a small amount of Hyoscyamus. The study will compare the effects of Cardiodoron® with a placebo to understand its effectiveness and safety.

The purpose of the study is to determine how well Cardiodoron® works in improving symptoms of functional cardiovascular disorders and to assess its safety. Participants will be randomly assigned to receive either the Cardiodoron® treatment or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The trial will last for a period of 89 days, during which participants will be monitored for changes in their symptoms and overall health.

Throughout the study, participants will have regular check-ups to track their progress and any changes in their condition. The researchers aim to identify suitable ways to measure the treatment’s success and any potential side effects. By the end of the study, the goal is to have a clear understanding of how Cardiodoron® can benefit those with functional cardiovascular disorders and to ensure it is safe for use. Participants’ feedback on their satisfaction with the treatment will also be collected to help evaluate its overall effectiveness and tolerability.

]]>